Wang E, et al. - In patients with intermediate hepatocellular carcinoma (HCC), researchers sought to validate tumor vascularity and hand-foot-skin reaction (HFSR) as strong predictors for the combination treatment of transarterial chemoembolization (TACE) and sorafenib. The potential candidates who would survive best from such treatment were also investigated. They analyzed 132 treatment-naive patients with intermediate HCC undergoing combination therapy of TACE and sorafenib and these subjects were followed for a median duration of 17.3 months. Findings revealed that tumor hypervascularity and development of ≥2 grade of HFSR within 60 days were identified as favorable predictive factors for the combination treatment of TACE and sorafenib. Longest survival was observed in patients with both of these factors, which might be the potential candidates.